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The increased incidence of pure red cell aplasia with an Eprex
formulation in uncoated rubber stopper syringes.
Background. The incidence of pure red cell aplasia (PRCA)
in chronic kidney disease patients treated with epoetins in-
creased substantially in 1998, was shown to be antibody me-
diated, and was associated predominantly with subcutaneous
administration of Eprex. A technical investigation identified
organic compounds leached from uncoated rubber stoppers in
prefilled syringes containing polysorbate 80 as the most proba-
ble cause of the increased immunogenicity.
Methods. This study investigated whether the incidence of
PRCA was higher for exposure to the product form contain-
ing leachates than for leachate-free product forms. Antibody-
mediated PRCA cases were classified according to indication,
product form, and route of administration. Exposure estimates
were obtained by country, indication, route of administration,
and product form.
Results. For 2001 to 2003, the PRCA incidence rate for pa-
tients with subcutaneous exposure to Eprex in prefilled syringes
with polysorbate 80 and uncoated rubber stoppers (leachates
present) was 4.61/10,000 patient years (95% CI 3.88–5.43) ver-
sus 0.26/10,000 patient years (95% CI 0.007–1.44) for syringes
with coated stoppers (leachates absent). The rate difference was
4.35/10,000 patient years (95% CI 3.44–5.26; P < 0.0001); the
rate ratio was 17 (95% CI 3.14–707). A substantial rate differ-
ence remained in sensitivity analyses that adjusted for exposure
to multiple product forms.
Conclusion. The epidemiologic data, together with the
chemical and immunologic data, support the hypothesis that
leachates from uncoated rubber syringe stoppers caused the in-
creased incidence of PRCA associated with Eprex. Currently,
all Eprex prefilled syringes contain fluoro-resin coated stop-
pers, which has contributed to decreased incidence of PRCA
with continued surveillance.
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Pure red cell aplasia (PRCA) is a rare disorder that
manifests itself as a severe, isolated anemia of sudden
onset, characterized by an almost complete absence of
red cell precursors in the bone marrow and a reticulo-
cyte count below 10 × 109/L [1]. Many potential causes
for PRCA have been reported, but most concern only
isolated case reports, and about 50% of cases have no
known cause [2]. Over the decade following its introduc-
tion in 1989, three cases of PRCA were associated with re-
combinant human erythropoietin (epoetin) treatment for
anemia in patients with chronic kidney disease (CKD) [3–
5]. From 1998 onward, however, an increasing number of
cases were reported [2]. These patients developed PRCA
due to neutralizing antibodies to epoetin that cross-react
with endogenous erythropoietin, and therefore, the con-
dition is termed antibody-mediated PRCA.
These cases occurred mainly in patients receiving epo-
etin alfa (EPREX/ERYPO; Ortho Biotech, a divi-
sion of Janssen-Cilag, Bridgewater, NJ, USA) outside the
USA, although a limited number received other epo-
etin products or a combination of products [6–10]. Ir-
respective of the type of epoetin administered, virtually
all of the cases occurred in CKD patients treated with
subcutaneous epoetin; no cases have occurred in cancer
patients [10]. To limit the increasing incidence of
antibody-mediated PRCA attributed to Eprex, risk-
mitigation initiatives were taken, including improved
cold chain storage and handling of Eprex [11], and a
switch to intravenous administration for CKD patients.
Health authorities in Europe formally contraindicated
subcutaneous administration of Eprex for CKD patients
in December 2002.
Technical and clinical investigations were initiated to
identify the cause of the observed increase in the im-
munogenicity of Eprex. Investigations into the manufac-
turing process for bulk drug substance and characteri-
zation of Eprex packaged into prefilled syringes did not
uncover any irregularities in the manufacturing process
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Fig. 1. Reverse-phase high-performance liquid chromatography. The large peak at 47 minutes is epoetin (EPO). The small peaks at 54 and 57
minutes are polysorbate 80. A series of extra peaks are present in the polysorbate 80 formulation of Eprex dispensed from prefilled syringes with
uncoated rubber stoppers (red) that are not present in the same product dispensed from syringes with coated stoppers (blue). Reproduced with
modification from Sharma et al with permission from the European Journal of Hospital Pharmacy [12].
or finished product that could be linked to the increased
incidence of PRCA [12]. During the course of this sys-
tematic investigation, however, a series of peaks were
observed on an experimental high-performance liquid
chromatography (HPLC) elution profile of Eprex from
prefilled syringes (Fig. 1) [12]. These peaks occurred
after the large epoetin peak and were identified by
mass spectrometry as organic compounds present in
the rubber stoppers [12]. It was reported in 2002 that
polysorbates and other nonionic detergents can leach
compounds out of plastics and rubber materials [13].
These leachates were only detected in the polysor-
bate 80 formulation of Eprex from prefilled syringes
with uncoated rubber stoppers. Eprex preparations con-
taining polysorbate 80 with fluoro-resin coated stop-
pers (FluroTec, Daikyo Seiko, Tokyo, Japan) did not
demonstrate these leachates, nor did those with uncoated
stoppers containing human serum albumin (HSA) in-
stead of polysorbate 80 as stabilizer. Leachates were
not present in other epoetin products, all of which
have coated stoppers. These data suggest that the
polysorbate 80 in the formulation had extracted these
compounds from the uncoated rubber stoppers [12].
The concentration of leachates in the syringes was vari-
able and increased with time and exposure to heat [12].
Studies using the well-characterized antigen ovalbumin
demonstrated that these leached compounds could act
as adjuvants when administered subcutaneously in mice
[12].
The in vivo findings for the adjuvant potential of
leachates led to the hypothesis that leachates present in
prefilled syringes of Eprex with uncoated rubber stop-
pers increased the risk of PRCA when this product was
administered subcutaneously in humans. To determine if
this hypothesis was consistent with the clinical data, the
incidence of PRCA by formulation, product form, and
route of administration were determined in a retrospec-
tive study using reported PRCA cases. This was possible
because prefilled syringes with coated stoppers had al-
ready been introduced in 2001 for some dosage strengths
and, in 2003, all dosage strengths of prefilled syringes with
the polysorbate 80 formulated Eprex were shipped with
coated stoppers.
METHODS
Reverse-phase HPLC
Reverse-phase HPLC analysis was carried out as previ-
ously described [12]. Briefly, the contents of epoetin alfa
syringes were injected into a Vydac C4 column. After a 5-
minute hold at 5% mobile phase B (0.06% trifluoroacetic
acid in acetonitrile), samples were eluted at a flow rate of
1.0 mL/minute by a linear gradient of 5% to 90% of mo-
bile phase B for 90 minutes. Monitoring was performed
at 280 nm.
Pharmacovigilance
An expanded review was undertaken of all sponta-
neous adverse events reported to Johnson & Johnson
relating to any epoetin product and any indication
for use, gathered from physicians, pharmacists, the
literature, medical representatives, and the patients
themselves. The Medical Dictionary for Regulatory
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Activities’ code terms was used to ensure that all pos-
sible cases of antibody-mediated PRCA were captured.
Loss of effect was defined as an absent or decreased re-
sponse to erythropoietin treatment in a patient who pre-
viously responded to such therapy, and characterized by
an increase in erythropoietin dosage and/or a sustained
decrease in hemoglobin. Antibody-mediated PRCA was
defined as either suspected or confirmed PRCA with a
positive anti-erythropoietin antibody test with any testing
method. Suspected PRCA was defined as loss of efficacy
with a decrease in hemoglobin of ≥2 g/dL in 30 days, need
for transfusions, reticulocytes <20,000 per mm3, platelet
count and white blood cell count normal, and bone mar-
row unavailable or unknown. Confirmed PRCA was de-
fined as suspected PRCA plus bone marrow with isolated
erythroblastopenia.
Exposure was estimated for patients receiving Eprex
(exclusively or in combination with another epoetin prod-
uct) for anemia in five disease areas: chronic kidney
disease receiving dialysis, chronic kidney disease not re-
ceiving dialysis, oncology, infectious disease (infection
with human immunodeficiency virus), and remaining use
(typically surgery). Estimates of the actual patient years
of exposure were obtained for each country by year (and
monthly from July 2002) for each indication, route of
administration, and formulation using drug-monitoring
data. The PRCA incidence rate (per 10,000 patient years)
was calculated by dividing the number of cases by the cor-
responding exposure (in 10,000 patient years). Reports
received by June 30, 2004 were included. When adjust-
ing for market exposure for the cumulative time period,
the incidence by date of onset is calculated with expo-
sure through the end of April 2004, not to the end of
June 2004. This accommodates an assumed minimum in-
terval of two month’s delay from the occurrence of LOE
to the determination of PRCA diagnosis and report to
the manufacturer; however, the lag time, in practice, may
be longer.
Case series analysis
Antibody-mediated PRCA cases in patients with
CKD were identified in the Johnson & Johnson clinical
database. The cases were attributed to Eprex if exposure
was more than one month with an adequate response and,
if there was a recent switch from another epoetin, there
was an ongoing response to that epoetin at the time of
the switch. Using information from treating physicians,
Counsel for International Organizations of Medical Sci-
ences forms, site assessments, and the company clinical
database, each case was evaluated and assigned to a cate-
gory based on exposure to a certain product presentation
(vials or prefilled syringes containing HSA or polysorbate
80 as stabilizer, coated or uncoated rubber syringe stop-
pers) and route of administration (intravenous or subcu-
taneous) of Eprex. The evaluation also took into account
the first date of availability for the different formulations
and product forms per country.
The following criteria were predetermined for the
purpose of retrospectively attributing the occurrence of
PRCA to a particular product exposure or route of ad-
ministration. The time frame of suspected exposure was
defined as one to 12 months prior to the onset of loss of
effect of Eprex. As there have been no cases of PRCA
with only intravenous exposure to Eprex, the nine cases
with mixed intravenous and subcutaneous exposure prior
to loss of effect were classified together with cases with
only subcutaneous exposure. Two cases of patients not on
dialysis or on peritoneal dialysis whose route of admin-
istration was unknown were attributed to subcutaneous
exposure, a reasonable assumption, as most of these pa-
tients do not routinely have intravenous access. Based on
the information of product availability over time in the
different countries, a decision tree was designed to allow
classification of each case into a specific category. If both
the product form and the dose were unknown, the case
was classified as unknown.
Statistical methods
Rate ratios, rate differences, and P value calculations
for the case series analyses were performed with STATA
version 8.0 (Stata Corporation, College Station, TX,
USA). Confidence intervals for the incidence rates were
based on the Poisson distribution for rare events.
RESULTS
Incidence
Based on reports received by Johnson & Johnson from
January 1, 1989 to June 30, 2004, 217 cases of antibody-
mediated PRCA were observed among patients with
chronic kidney disease. Of these, 206 cases were at-
tributed to epoetin alfa marketed under the EPREX/
ERYPO trade name, 23 of which had exposure to both
Eprex and another epoetin. Of the 206 cases, 192 had
only subcutaneous exposure, nine had both intravenous
and subcutaneous exposure, and for five, the route was
unknown. Assigning those with mixed route exposure to
the subcutaneous route and excluding those cases with
unknown route, the overall rate of antibody-mediated
PRCA was 1.61 (95% CI 1.40–1.85) per 10,000 patient
years of subcutaneous exposure (201 cases/1,244,970 pa-
tient years) versus 0 (95% CI 0–0.04) per 10,000 patient
years of intravenous exposure (0 cases/871,098 patient
years) for the cumulative time period.
The occurrence of PRCA began to increase in 1998
and peaked from 2001 to 2002 (analyzed by date of on-
set rather than date of report). Subcutaneous exposure
to the polysorbate 80 formulation with uncoated syringe
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Fig. 2. Onset of antibody-mediated pure red cell aplasia (PRCA) and worldwide Eprex exposure for nephrology by calendar time. The bar graph
shows the number of antibody-mediated PRCA cases by year in which the loss of effect occurred. Four cases are not shown due to unknown year
of loss of effect. Two additional cases occurred in the period January-April 2004. Eprex exposure is shown linearly for intravenous exposure to
all product forms and subcutaneous exposure to the human serum albumin formulation, the polysorbate 80 formulation in syringes with uncoated
stoppers, polysorbate 80 in vials, and polysorbate 80 in syringes with coated stoppers. The polysorbate 80 formulation of Eprex was introduced in
1998.
stoppers peaked with 158,650 patient years in 2002, while
onset of PRCA peaked in 2003 with 71 cases (see Fig. 2).
In the period January through April 2004, two new cases
were reported.
Case series analysis
Classification of PRCA cases by formulation of Eprex
within 1 to 12 months of onset is shown in Table 1. In all,
182 cases had subcutaneous exposure to prefilled syringes
containing a formulation with polysorbate 80 stabilizer
and uncoated rubber stoppers. In 46 of the 182 cases, an
assumption was made that the product form was a pre-
filled syringe and not a single-use vial based on product
availability in the country. Ten cases had exposure to only
HSA-containing product (vials or prefilled syringes), and
one had exposure to only prefilled syringes with polysor-
bate 80 and coated stoppers. Insufficient information was
available to classify 12 cases.
Exposure to Eprex over the cumulative period 1989
to April 2004, and for the period 2001 to 2003, when
exposure estimation and case ascertainment were most
complete (due to publicity), and when both uncoated
and coated stopper formulations were on the market, is
shown in Tables 2 and 3. For the cumulative period, the
incidence rate of PRCA in patients who received Eprex
from syringes with polysorbate 80 and uncoated rubber
stoppers was 3.43/10,000 patient years (95% CI 2.95–3.96)
versus 0.23/10,000 patient years (95% CI 0.006–1.28) for
products with polysorbate 80 and coated stoppers. The
rate difference between these products was 3.20/10,000
patient years (95% CI 2.53–3.87; P < 0.0001), and the
rate ratio was 15 (95% CI 2.7–594). For the period 2001
to 2003, the incidence rate of PRCA in patients who re-
ceived Eprex from syringes with uncoated rubber stop-
pers and polysorbate 80 was 4.61/10,000 patient years
(95% CI 3.88–5.43) versus 0.26/10,000 patient years (95%
CI 0.007–1.44) for products with coated stoppers and
polysorbate 80. The rate difference between these prod-
ucts was 4.35/10,000 patient years (95% CI 3.44–5.26; P <
0.0001), and the rate ratio was 17 (95% CI 3.14–707). Sim-
ilar results were obtained comparing the incidence rate of
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Table 1. Cases of antibody-mediated pure red cell aplasia in chronic
kidney disease patients reported between January 1, 1989 and June 30,
2004 were classified by form of Eprex exposure
Eprex form by subcutaneous
route within 1 to 12 months 1989–April 2004 2001–2003
of onset of loss of effect (total) (peak)
Uncoated rubber stopper, polysorbate
80 formulation, prefilled syringe
151 116
Coated stopper, polysorbate 80
formulation, prefilled syringe
1 1
Human serum albumin formulation 10 2
Polysorbate 80 formulation, vials 1 1
Mixed:
Uncoated rubber stopper, polysorbate
80 formulation, prefilled syringe,
and coated stopper, polysorbate 80
formulation, prefilled syringe
27 25
Mixed:
Uncoated rubber stopper,
polysorbate 80 formulation,
prefilled syringe, and human serum
albumin formulation
4 1
Unknown 12 9
Total 206 155
PRCA in patients who received Eprex from syringes with
uncoated rubber stoppers and polysorbate 80 against that
for the subtotal of all other subcutaneous forms combined
(Tables 2 and 3).
To avoid bias, the analysis was adjusted to account for
mixed exposure in both the cases and the reference popu-
lation. Cases with mixed exposure accounted for less than
20% of the total with known exposure. As shown in the
footnotes to Tables 2 and 3, estimates for rate differences
and ratios were decreased by less than 20% when cases
with mixed exposure were excluded. For 2001 to 2003, ap-
proximately 25% of subcutaneous exposure to prefilled
syringes with polysorbate 80 and coated stoppers was at-
tributed to replacement of syringes with uncoated stop-
pers; lower mixed usage was anticipated for other forms.
In sensitivity analyses, exposure estimates for product
forms other than prefilled syringes with uncoated rub-
ber stoppers and polysorbate 80 were decreased by 25%
based on observed temporal trends in usage patterns. The
sum of exposure subtracted from other forms was added
to exposure to prefilled syringes with uncoated rubber
stoppers and polysorbate 80. The rate difference between
uncoated syringe stoppers and coated syringe stoppers
for 2001 to 2003 was 3.89/10,000 patient-years (95% CI
2.92–4.86; P = 0.0001), and the rate ratio was 12 (95%
CI 2.2–448) (see Table 4). Results were similar for the
cumulative period 1989 to April 2004.
DISCUSSION
Before 1998, Eprex was formulated with HSA as stabi-
lizer. It was replaced with polysorbate 80 for most coun-
tries outside the USA to preclude hypothetical risk of
transmission of infectious diseases by HSA [10]. It should
be noted that multidose vials containing HSA continue
to be available in Canada, and prefilled syringes contain-
ing HSA are available in Turkey. Overall, the case series
shows a clear temporal association between the increased
incidence of antibody-mediated PRCA and the replace-
ment of HSA with polysorbate 80 in countries outside
the USA (Fig. 2). Detailed analysis of the case series re-
vealed a substantial difference in incidence rates between
patients with subcutaneous exposure to prefilled syringes
with polysorbate 80 and uncoated rubber stoppers and
all other product forms, suggesting that the introduction
of the stabilizer polysorbate 80 in combination with the
uncoated rubber stoppers had a major impact on the im-
munogenicity of Eprex given subcutaneously.
Subcutaneous administration of Eprex in CKD pa-
tients has decreased markedly since its contraindication
in Europe; however, a low level of subcutaneous use con-
tinues. For January through April 2004, subcutaneous
exposure to forms containing polysorbate 80 was 5000
patient years, and for forms containing human serum al-
bumin, 4600 patient years. This population was included
in the case series reported here. The analysis shows that
the immunogenicity of Eprex in prefilled syringes with
coated stoppers is substantially lower than that of the
product with uncoated rubber stoppers. These findings
correlate with the results of the technical investigation,
which demonstrated that the combination of polysor-
bate 80 and uncoated rubber syringe stoppers introduced
leachates from the stoppers into the product [12].
Although rubber stoppers were in use from the first
introduction of Eprex prefilled syringes for subcuta-
neous administration in 1994, the replacement of HSA
with polysorbate 80 in 1998 appears to have effected a
change in the leaching of potentially immunogenic com-
pounds from the rubber stoppers of epoetin presenta-
tions most commonly used in patients with CKD. Epoetin
beta and darbepoetin syringes for subcutaneous injection
were introduced after those of Eprex and have coated
stoppers; no leachates were detected in these products,
despite the presence of polysorbate stabilizers [12]. The
enhanced immune response in mice in the presence of
rubber leachates supports the hypothesis that these com-
pounds could act as adjuvants to increase the immuno-
genicity of Eprex in humans [12].
The question remains why relatively few cases of
antibody-mediated PRCA have occurred, and why some
(a very few) cases have occurred in patients treated only
with products other than Eprex. Multiple factors are re-
quired to trigger a T-cell–mediated immune response and
loss of tolerance. These include the presence of a suffi-
cient number of erythropoietin-recognizing T cells and B
cells in the patient, as well as erythropoietin and an adju-
vant. The relatively low frequency of cases is most likely
due to the relatively low and variable concentration of
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Table 2. Case count, Eprex exposure, and incidence rate of antibody-mediated pure red cell aplasia in chronic kidney disease patients received
from January 1, 1989 to June 30, 2004
Case Exposure Incidence rate 95% confidence interval
Eprex form by subcutaneous route only count (patient-years)b (per 10,000 patient-years) (Poisson exact)
Uncoated rubber stopper, polysorbate 80
formulation, prefilled syringe
182a 530,991 3.43 2.95–3.96
Coated stopper, polysorbate 80 formulation,
prefilled syringe
1 43,659 0.23 0.006–1.28
Human serum albumin formulation 10 598,690 0.17 0.08–0.31
Polysorbate 80 formulation, vials 1 71,630 0.14 0.004–0.78
Total (case count where onset and form are known) 194 1,244,970 1.56 1.35–1.79
Subtotal: all subcutaneous forms except uncoated
stopper polysorbate 80 prefilled syringe
12 713,979 0.17 0.09–0.29
Comparison of uncoated stopper versus coated stopper polysorbate 80 prefilled syringe with mixed-exposure cases included (N = 31) and without adjustment of
exposure denominator for mixed exposure: rate difference = 3.20/10,000 patient-years (95% CI 2.53–3.87); P < 0.0001, rate ratio = 15 (95% CI 2.7–594). Comparison of
uncoated stopper versus coated stopper polysorbate 80 prefilled syringe with mixed-exposure cases excluded (N = 31) and without adjustment of exposure denominator
for mixed exposure: rate difference = 2.62/10,000 patient-years (95% CI 1.98–3.25); P < 0.0001, rate ratio = 12 (95% CI 2.2–494).
aPRCA cases with mixed exposure (N = 31) to both uncoated stopper polysorbate 80 prefilled syringe and either coated stopper polysorbate 80 prefilled syringe (N
= 27) or human serum albumin formulations (N = 4) were assigned to the uncoated stopper category. Eprex form was unknown for 12 cases.
bWhen adjusting for market exposure, the actual exposure data used were calculated to the end of April 2004. This accommodated an assumed minimum interval of
two months’ delay from identification of loss of effect to the actual report to the sponsor (June 2004), and helped address the latency from exposure to development of
disease. Exposure was not adjusted for patients that switched forms or routes within a 12-month period.
Table 3. Comparison by form 2001 to 2003: Case count, Eprex exposure, and incidence rate of antibody-mediated pure red cell aplasia in chronic
kidney disease patients with onset of loss of effect during 2001 to 2003 and received by June 30, 2004
Case Exposure Incidence rate 95% confidence interval
Eprex form by subcutaneous route only count (patient-years)b (per 10,000 patient-years) (Poisson exact)
Uncoated rubber stopper, polysorbate 80
formulation, prefilled syringe
142a 308,232 4.61 3.88–5.43
Coated stopper, polysorbate 80 formulation,
prefilled syringe
1 38,608 0.26 0.007–1.44
Human serum albumin formulation 2 42,305 0.47 0.057–1.71
Polysorbate 80 formulation, vials 1 27,794 0.36 0.009–2.00
Total (case count where onset and form are known) 146 416,939 3.50 2.96–4.12
Subtotal: all subcutaneous forms except uncoated
stopper polysorbate 80 prefilled syringe
4 108,707 0.37 0.10–0.94
Comparison of uncoated stopper versus coated stopper polysorbate 80 prefilled syringe without adjustment of exposure denominator for mixed exposure: rate
difference = 4.35/10,000 patient-years (95% CI 3.44–5.26); P < 0.0001, rate ratio = 17 (95% CI 3.14–707). Comparison of uncoated stopper versus coated stopper
polysorbate 80 prefilled syringe with mixed cases excluded without adjustment of exposure denominator for mixed exposure: rate difference = 3.50/10,000 patient-years
(95% CI 2.65–4.36); P < 0.0001, rate ratio = 15 (95% CI 2.6–579).
aPRCA cases with mixed exposure to both uncoated stopper polysorbate 80 prefilled syringe and either coated stopper polysorbate 80 prefilled syringe (N = 25) or
human serum albumin formulations (N = 1) were assigned to the uncoated stopper category. Eprex form was unknown for nine cases.
bWhen adjusting for market exposure, the actual exposure data used were calculated to the end of April 2004. This accommodated an assumed minimum interval of
two months’ delay from identification of loss of effect to the actual report to the sponsor (June 2004), and helped address the latency from exposure to development of
disease. Exposure was not adjusted for patients that switched forms or routes within a 12-month period.
leached adjuvants in Eprex, and the low probability of a
patient having a population of T cells and B cells that can
recognize erythropoietin. Other as yet unidentified pre-
disposing patient characteristics could also play a role.
The cases with other products probably represent
the very rare background incidence rate of antibody-
mediated PRCA that occurs due to a combination of pres-
ence of a sufficient number of erythropoietin-recognizing
T cells and B cells (loss of erythropoietin tolerance), and
perhaps the presence of some natural or bystander ad-
juvant. The clinical experience with antibody-mediated
PRCA—such as the prevalence in CKD patients and as-
sociation with subcutaneous administration [2, 6], which
would exacerbate any immunogenicity [14]—suggests
that its causality is likely to be multifactorial. Thus, only
in relatively few patients would all the necessary factors
occur together. Possible reasons for the apparent protec-
tion of cancer patients may include a shorter duration of
epoetin treatment and nonspecific immunosuppression
[2].
The reported mean time between first exposure to
Eprex and the initial diagnosis of antibody-mediated
PRCA is 9.1 months (range 0.3–82) [15]. With some delay
in reporting, it is anticipated that a few new cases from
exposure to uncoated stopper forms and leachates may
still occur. Once a sufficient time period has elapsed since
the replacement of the uncoated stopper form with the
coated stopper form and the last exposure to leachates,
the incidence rate for Eprex is expected to drop to the
background incidence rate observed for all subcutaneous
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Table 4. Sensitivity analysis for mixed usage of forms 2001 to 2003: Incidence rate of antibody-mediated pure red cell aplasia in chronic kidney
disease patients with onset of loss of effect during 2001 to 2003 and received by June 30, 2004 with exposure adjusted for mixed usage of forms
Unadjusted Exposure adjusted 25% Incidence rate (per 10,000 95% confidence
Case market exposure for mixed usage of patient-years) using adjusted interval
Eprex form by subcutaneous route only count (patient-years) forms over timea exposure for mixed use (Poisson exact)
Uncoated stopper, polysorbate 80
formulation, prefilled syringe
142b 308,232 335,409 4.23 3.57–4.99
Coated stopper, polysorbate 80
formulation, prefilled syringe
1 38,608 28,956 0.34 0.009–1.92
Human serum albumin formulation 2 42,305 31,729 0.63 0.08–2.28
Polysorbate 80 formulation, vials 1 27,794 20,846 0.48 0.01–2.67
Subtotal: all subcutaneous forms except
uncoated stopper polysorbate 80
prefilled syringe
4 108,707 81,530 0.49 0.13–1.26
Comparison of uncoated stopper versus coated stopper polysorbate 80 prefilled syringe with 25% adjustment of exposure denominator for mixed exposure: rate
difference = 3.89 per 10,000 patient-years (95% CI 2.92–4.86); P = 0.0001, rate ratio = 12 (95% CI 2.2–448). Comparison of uncoated stopper versus all other
subcutaneous forms with 25% adjustment of exposure denominator for mixed exposure: rate difference = 3.74 per 10,000 patient-years (95% CI 2.90–4.59); P < 0.0001,
rate ratio = 8.6 (95% CI 3.3–32).
aExposure for the uncoated stopper polysorbate 80 prefilled syringe is adjusted by adding the sum of exposure subtracted from the other forms.
bPRCA cases with mixed exposure to both uncoated stopper polysorbate 80 prefilled syringe and either coated stopper polysorbate 80 prefilled syringe (N = 25) or
human serum albumin formulations (N = 1) were assigned to the uncoated stopper category. Eprex form was unknown for nine cases.
forms, excluding uncoated rubber syringe stoppers, of
approximately 0.5/10,000 patient-years of subcutaneous
exposure.
The limitations of this study include the retrospec-
tive nature of the analysis and reliance on postmarket-
ing surveillance data, which can be incomplete. The re-
porting of PRCA with Eprex could have been stimulated
by the medical literature compared to the reporting of
PRCA with other products. Additionally, different man-
ufacturers may use different definitions or methods for
calculating the incidence rate for their product and may
not specify the peak period of reporting, subcutaneous
versus all routes of administration, and the renal indica-
tion versus all indications. Consequently, it is not valid
to quantitatively compare rates between manufacturers.
However, all of the cases analyzed in this manuscript were
classified by the same definition. Since there is no reason
to expect a bias in reporting by formulation, we believe
the comparison across Eprex forms is valid. The incidence
rates reported here are consistent with a recent report by
Bennett et al [15]. Sensitivity analyses were done to try
to adjust for mixed cases and mixed exposure. However,
these analyses were limited to excluding the mixed ex-
posure cases (reasonable in the context of the chemical
and immunologic findings), and reassigning a proportion
of the uncoated stopper exposure to account for the fact
that there was mixed exposure.
CONCLUSION
The results of the case series analysis, taken together
with the identification of rubber leachates in the polysor-
bate 80 formulation from prefilled syringes of Eprex with
uncoated rubber stoppers and the evidence of their ca-
pacity to increase the immunogenicity in experimental
animals, suggest that these leachates were the critical con-
tributory factor in the increased incidence of antibody-
mediated PRCA attributed to Eprex. In April 2003,
distribution of Eprex prefilled syringes with uncoated
rubber stoppers was replaced by syringes containing stop-
pers with fluoro-resin coating, which provides a barrier
that minimizes the interaction between the drug and the
stopper and prevents extraction of organic compounds.
Eprex prefilled syringes with coated stoppers do not re-
lease leachates, and have not resulted in increased inci-
dence of PRCA with continued intensive surveillance.
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